Latest Regulatory Review News

Page 4 of 9
Elanor Commercial Property Fund has lodged an application with the Takeovers Panel, alleging significant disclosure deficiencies in Lederer’s off-market takeover bid and seeking a replacement bidder’s statement.
Eva Park
Eva Park
3 Sept 2025
Lumos Diagnostics has secured a significant follow-on contract with Aptatek Biosciences to push forward the development of an innovative in-home monitoring device for Phenylketonuria (PKU), a rare genetic disorder. This next phase aims to bring the FDA Breakthrough Device-designated PheCheck™ closer to clinical trials and commercial readiness.
Ada Torres
Ada Torres
1 Sept 2025
Island Pharmaceuticals has formally requested a Type C meeting with the US FDA to discuss accelerating approval of its antiviral Galidesivir for Marburg virus using the Animal Rule pathway.
Victor Sage
Victor Sage
1 Sept 2025
Mad Paws Holdings has completed the divestment of its Pet Chemist business and announced the resignation of Executive Director Howard Humphreys, advancing its proposed acquisition by Rover Group.
Victor Sage
Victor Sage
29 Aug 2025
PEXA Group Limited reported a 16% revenue increase to $393.6 million for FY25, driven by growth across its Australian Exchange, UK International business, and Digital Solutions segments. Despite a statutory net loss of $76.1 million due to impairments and deferred tax derecognition, core EBITDA rose 21% with improved margins.
Sophie Babbage
Sophie Babbage
29 Aug 2025
Manuka Resources’ subsidiary Trans-Tasman Resources has entered a pivotal phase as an expert panel starts assessing its Fast Track application for seabed mining off New Zealand’s coast, aiming to unlock significant economic and mineral export potential.
Maxwell Dee
Maxwell Dee
21 Aug 2025
Heartland Group Holdings Limited reported an underlying NPAT of NZD 46.9 million for FY2025, meeting guidance, while setting ambitious growth and efficiency targets for FY2026.
Claire Turing
Claire Turing
21 Aug 2025
Prescient Therapeutics reported an 11.1% reduction in net loss for FY2025, progressing its lead candidate PTX-100 into Phase 2a trials with FDA Fast Track and Orphan Drug designations, supported by a recent $9.8 million capital raise.
Ada Torres
Ada Torres
20 Aug 2025
The Lottery Corporation has reported resilient FY25 results with a dividend increase and strong digital channel growth, despite below-average jackpot outcomes and economic headwinds.
Victor Sage
Victor Sage
20 Aug 2025
Ainsworth Game Technology reported a 25% revenue increase for the first half of 2025, yet underlying profits slipped due to margin pressures from tariffs and product mix shifts. The launch of the A-Star Raptor dual screen cabinet bolstered Asia Pacific sales, while challenges persist in Latin America and online segments.
Victor Sage
Victor Sage
19 Aug 2025
The Takeovers Panel has declined to review its earlier ruling on Keybridge Capital Limited, affirming no unacceptable circumstances exist. This decision closes a regulatory chapter but leaves some questions about future governance.
Claire Turing
Claire Turing
12 Aug 2025
Genesis Energy, alongside Mercury, Meridian, and Contact, has inked 10-year agreements to fortify New Zealand’s energy security through Huntly Power Station capacity and fuel reserves. This strategic move aims to prevent supply crunches like those experienced in winter 2024.
Maxwell Dee
Maxwell Dee
4 Aug 2025